CTRL Therapeutics
Signal active
Organization
Contact Information
Overview
CTRL Therapeutics operates a biotechnology company that researches on cell therapy development and treatment. It is based in Toronto, Canada.
About
Industries
Biotechnology, Life Science, Health Care, Medical, Therapeutics
Founded
2019
Employees
1-10
Headquarters locations
Toronto, Ontario, Canada, North America
Social
Profile Resume
CTRL Therapeutics headquartered in North America, operates in the Biotechnology, Life Science, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $200.0M in funding across 20 round(s). With a team of 1-10 employees, CTRL Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - CTRL Therapeutics, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
1
Investors
3
Lead Investors
0
Total Funding Amount
$10.0M
Details
1
CTRL Therapeutics has raised a total of $10.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2023 | Seed | 10.0M |
Investors
CTRL Therapeutics is funded by 6 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| General Catalyst | - | FUNDING ROUND - General Catalyst | 10.0M |
| Intermountain Healthcare | - | FUNDING ROUND - Intermountain Healthcare | 10.0M |
| CTRL Therapeutics | - | FUNDING ROUND - CTRL Therapeutics | 10.0M |
| FACIT | - | FUNDING ROUND - FACIT | 10.0M |
Recent Activity
News
May 25, 2024
LinkedIn - Norbert Bischofberger on LinkedIn: We are thrilled to welcome someone of Deb's expertise to our team. As a…
News
Apr 30, 2024
BioSpace - Cell Expansion Market Experiencing Rapid Growth 12.32% by 2032
News
Apr 22, 2024
BioSpace - Cell Therapy Market Size to Grow At 22.67% CAGR Till 2033
News
Feb 20, 2024
LinkedIn - cTRL Therapeutics on LinkedIn: #cancer
News
Dec 12, 2023
cTRL Therapeutics Appoints Ruben Rodriguez, Ph.D., as Head of Research
News
Nov 01, 2023
cTRL Therapeutics Appoints Derrell D. Porter, M.D., as Chief Executive Officer